Antibody drug Evusheld can fight Omicron variant: AstraZeneca
AstraZeneca, a British-Swedish pharmaceutical company, has reported that its antibody medication 'Evusheld' is effective against Covid-19's novel vaccine-evading Omicron strain.
AstraZeneca, a British-Swedish pharmaceutical company, has reported that its antibody medication 'Evusheld' is effective against Covid-19's novel vaccine-evading Omicron strain.
Imperial scientists had aimed to use the technology to design a Covid-19 jab. However, it never progressed further than stage two clinical testing.
"No specific risk factors or definitive cause for TTS following Covid-19 vaccination have been identified and AstraZeneca continues to perform and support ongoing investigations of potential mechanisms," the study noted.
Previous studies have shown that the Oxford jab is more effective in generating T-cells than mRNA vaccines like Pfizer and Moderna.
The authority will negotiate with Siam Bioscience Co. and recommend that the manufacturer supply the vaccine to Thailand
The AstraZeneca doses are coming from the advance purchase agreement the government struck with the company and that these doses, which will be manufactured in the United States
The study aims to enroll 2,250 participants from the UK, South Africa, Brazil, and Poland to build immunity against the Beta Covid variant
European Commission President Ursula von der Leyen welcomed the decision, saying that the EU's vaccination programme was built on a sound legal basis
The analysis suggests that the Pfizer-BioNTech vaccine is 96 per cent effective against hospitalisation after two doses, while the Oxford-AstraZeneca vaccine is 92 per cent effective against hospitalisation after two doses.
The clarification came after Marco Cavaleri, head of the EMA's vaccine strategy, was quoted as saying by an Italian newspaper that the vaccine shots should not be administered to people aged over 60 and younger age groups amid fears over very rare blood clotting.
